Regeneron Pharmaceuticals leadership interviews test whether candidates understand how to lead a biopharmaceutical company through the specific strategic challenges that CEO Leonard Schleifer has managed since founding the company in 1988 and that the leadership team must address today – managing the transition from EYLEA-dependent revenue toward the DUPIXENT-led multi-indication portfolio while defending EYLEA's market position against biosimilar competition, sustaining the high R&D investment model that has produced the VelocImmune platform and the Regeneron Genetics Center as long-term scientific advantages, governing the strategic partnership with Sanofi that provides commercial scale for DUPIXENT and LIBTAYO while managing the governance tensions that major collaboration relationships inevitably create, and preserving the founder-built scientific culture that distinguishes Regeneron's discovery capability from larger pharmaceutical companies whose commercial orientation can crowd out the long-horizon research investments that produce first-in-class medicines. Leadership at Regeneron spans portfolio strategy management through product lifecycle transitions (where EYLEA's leadership in wet AMD faces a structural challenge from biosimilar aflibercept entry that will reshape the ophthalmology market and require Regeneron to defend EYLEA HD's clinical differentiation while rebalancing the commercial and financial infrastructure around DUPIXENT's growing multi-indication franchise), Sanofi partnership governance and strategic alignment (where the collaboration agreement that gives Sanofi global commercialization leadership for DUPIXENT and LIBTAYO provides Regeneron access to commercial capabilities and financial support that an independent company would struggle to replicate, while creating governance interdependencies on major product decisions that can slow strategic response and where the two companies' long-term portfolio interests may not always align perfectly), R&D pipeline allocation and platform investment (where leadership must balance investment between the inflammation and immunology programs that have produced Regeneron's approved portfolio, the oncology programs centered on LIBTAYO and combination IO strategies, the ophthalmology pipeline extending beyond EYLEA, and the emerging platforms in cardiovascular disease, rare disease, and infectious disease where the Regeneron Genetics Center's human genetics insights are generating novel targets), and science-first culture leadership (where Schleifer and Chief Scientific Officer George Yancopoulos have built a distinctive culture where scientific rigor and long-term research investment take precedence over commercial optimization, and where maintaining this culture's integrity as the commercial organization grows to support DUPIXENT's multi-indication franchise requires deliberate leadership choices about organizational design, incentive structures, and the signals that senior leaders send through their decisions). Interviewers evaluate whether candidates understand portfolio lifecycle transition management, major pharmaceutical partnership governance, R&D pipeline strategic allocation, and science-first culture leadership at commercial scale.

Start your free Regeneron Pharmaceuticals Leadership practice session.

What interviewers actually evaluate

Portfolio Lifecycle Management, Sanofi Partnership Governance, and R&D Pipeline Strategic Allocation

Regeneron leadership interviews probe whether candidates understand how leading a science-first biopharmaceutical company differs from leading a commercial pharmaceutical company in the R&D investment logic (Regeneron's sustained competitive advantage is derived from its discovery platforms – VelocImmune for rapid antibody generation, VelociGene for target validation in genetically modified mice, and the Regeneron Genetics Center for human genetics-driven target identification – and leadership decisions about how much to invest in maintaining and extending these platforms versus deploying capital for commercial infrastructure or shareholder returns reflect a fundamentally different prioritization logic than a pharmaceutical company that relies on licensing or acquisition to build its pipeline, and leadership candidates who understand this must articulate how sustained platform investment creates competitive advantage that compounding licensing strategies cannot replicate), the partnership governance challenge at scale (the Sanofi collaboration covers Regeneron's two largest commercial products and governs major decisions about their development and commercialization through joint committees that require alignment between two publicly traded companies with different shareholders, different portfolio contexts, and different strategic objectives – Regeneron leaders who understand how to advance Regeneron's strategic interests through the collaboration governance structure without creating counterproductive friction with a partner on whom Regeneron's commercial success depends demonstrate the strategic sophistication that major pharmaceutical partnerships require), and the biosimilar disruption strategic response (EYLEA's revenue trajectory under biosimilar competition is the most visible near-term strategic challenge for Regeneron leadership, and the correct response requires simultaneously defending EYLEA HD in the retina specialist market through clinical differentiation, managing the financial transition as EYLEA's contribution to total revenue declines, and ensuring that DUPIXENT's growth trajectory and pipeline execution provide the long-term revenue sustainability that EYLEA's maturation reduces – a portfolio management challenge that requires leadership to resist the temptation to overinvest in EYLEA defense at the expense of DUPIXENT expansion and pipeline advancement).

The Inflation Reduction Act's Medicare drug price negotiation provisions create a new strategic environment for Regeneron leadership: EYLEA's Part B negotiation and the potential future application of IRA negotiation to DUPIXENT represent a fundamental change in the pricing environment for Regeneron's most important commercial products, requiring leadership to engage with health policy and evaluate how pricing pressure affects the R&D investment model that produces the innovation the IRA's proponents want to preserve while addressing the affordability concerns that motivated the legislation.

What gets scored in every session

Specific, sentence-level feedback.

Dimension What it measures How to answer
Portfolio lifecycle transition leadership Do you understand how to lead Regeneron through the transition from EYLEA-dominated revenue to DUPIXENT multi-indication leadership while managing biosimilar competition for EYLEA – how to allocate commercial investment between defending EYLEA and accelerating DUPIXENT indication expansion, what communication strategy manages investor expectations during the transition, and how to ensure that operational and financial infrastructure scales with DUPIXENT's growth? We flag leadership answers that frame the EYLEA-to-DUPIXENT transition as a binary switch rather than a managed portfolio rebalancing challenge. Commercial investment reallocation, investor transition narrative, DUPIXENT operational scale readiness
Sanofi collaboration governance and strategic alignment Can you describe how to manage the Sanofi partnership at the leadership level – how to advance Regeneron's strategic priorities through joint governance committees, how to address situations where Regeneron's commercial interests and Sanofi's portfolio priorities diverge, and how to maintain a productive long-term partnership relationship while ensuring that Regeneron's independence and scientific mission are protected? We score whether your partnership governance approach engages with the specific dynamics of a major pharmaceutical collaboration rather than treating co-development as standard vendor management. Joint committee strategic positioning, commercial interest divergence management, partnership independence preservation
R&D pipeline allocation and platform investment strategy Do you understand how to allocate R&D investment across Regeneron's therapeutic area portfolio – how to prioritize inflammation, oncology, ophthalmology, and emerging platform investments against each other, what criteria determine when a pipeline asset justifies Phase 3 investment, and how to communicate the long-term value of platform investments like the Regeneron Genetics Center to investors who apply near-term financial metrics? We detect leadership answers that treat pipeline allocation as a financial optimization exercise without engaging with scientific differentiation as a strategic criterion. Therapeutic area investment prioritization, platform vs program investment balance, R&D value communication
Science-first culture leadership at commercial scale Can you describe how Leonard Schleifer's leadership approach preserves scientific culture in a company with a growing commercial organization – what organizational design choices and leadership behaviors signal that scientific rigor takes precedence over commercial optimization, how to address cultural drift as the commercial workforce grows, and what specific leadership actions in 2025 signal genuine commitment to the science-first culture versus institutional messaging? We flag leadership answers that treat culture as values statements rather than a behavioral and structural design challenge. Scientific culture behavioral signals, commercial organization cultural integration, founder culture leadership model

How a session works

Step 1: Choose a Regeneron Pharmaceuticals leadership scenario – EYLEA biosimilar competition and portfolio lifecycle transition leadership, Sanofi collaboration governance and strategic alignment, R&D pipeline allocation and platform investment strategy, or science-first culture leadership during commercial scale-up.

Step 2: The AI interviewer asks realistic Regeneron-style questions: how you would advise CEO Schleifer on the resource allocation decision between investing an additional $500 million over three years in DUPIXENT commercial expansion across new indications including COPD versus investing the same amount in accelerating three next-generation inflammation biologic candidates in Phase 2 development that use Regeneron Genetics Center targets to address patient populations where DUPIXENT has limited efficacy – including how you would frame this as a portfolio strategy decision rather than a budget allocation exercise and what information would be most important for making the decision, how you would manage the situation where Regeneron and Sanofi disagree about the commercial investment level that should support LIBTAYO's non-small cell lung cancer indication – where Regeneron believes the indication requires substantially more investment than Sanofi has committed to the joint commercialization plan, but Sanofi is prioritizing its other IO assets in its own commercial strategy, or how you would design the communication strategy to explain Regeneron's financial trajectory to investors during the period when EYLEA's annual net revenue is declining by $300-400 million per year due to biosimilar competition while DUPIXENT's annual revenue growth is approximately $800-900 million per year, ensuring that investors understand the portfolio-level growth story without dismissing the EYLEA headwind.

Step 3: You respond as you would in the actual interview. The system scores your answer on portfolio lifecycle management, partnership governance, R&D pipeline allocation, and science-first culture leadership.

Step 4: You get sentence-level feedback on what demonstrated genuine biopharmaceutical leadership expertise and what needs stronger portfolio strategy analysis or Sanofi collaboration governance specificity.

Frequently Asked Questions

How has Leonard Schleifer's founding leadership shaped Regeneron's strategic identity?
Schleifer founded Regeneron in 1988 with co-founder George Yancopoulos based on a scientific vision of integrated drug discovery – building the tools and genetic technologies that would make antibody drug discovery faster and more productive, rather than acquiring licenses to others' discoveries. This founding orientation established several features that distinguish Regeneron: sustained investment in discovery platform technologies like VelocImmune and VelociGene that provide proprietary advantages in drug generation, a culture of intellectual honesty where the scientific case for a program must be genuinely strong before advancing to expensive late-stage development, and a long-term investment philosophy where R&D investments are evaluated over decade-length horizons rather than quarterly earnings cycles. Schleifer's 37-year tenure as CEO is exceptional in the pharmaceutical industry and creates a leadership continuity and cultural consistency that most large pharmaceutical companies cannot match – the values and priorities he articulates today are the same ones that shaped the decisions that produced EYLEA and DUPIXENT from early research programs.

How does the EYLEA to DUPIXENT portfolio transition affect Regeneron's strategic priorities?
EYLEA's revenue trajectory has been shaped by two converging forces: the natural maturation of a 13-year-old product whose core patient population in wet AMD is largely penetrated in the US, and the entry of biosimilar aflibercept products that create price competition and payer formulary pressure. EYLEA HD's clinical differentiation in extended dosing provides a defense of the value segment of the market, but the overall aflibercept market will experience price compression that reduces EYLEA's total net revenue contribution over time. DUPIXENT's growth across its indication portfolio – with significant remaining patient penetration opportunity even in the established atopic dermatitis indication and multiple new indications including COPD adding incremental patient populations – provides the long-term revenue growth engine that sustains Regeneron's financial profile as EYLEA matures. Leadership's allocation of commercial investment, manufacturing capacity, and pipeline resources toward DUPIXENT's continued expansion is the primary strategic execution priority of the portfolio transition period.

How does the Sanofi collaboration shape Regeneron's strategic options?
The Regeneron-Sanofi collaboration, which covers DUPIXENT, LIBTAYO, and several other assets, provides Regeneron access to Sanofi's global commercial infrastructure – sales forces in markets where Regeneron does not have its own presence, regulatory and medical affairs capabilities in markets where Sanofi has established operations, and capital support for development programs that the collaboration funds jointly. These resources enable DUPIXENT's global commercial scale that would take Regeneron a decade to build independently. The governance structure creates interdependencies: major decisions about DUPIXENT and LIBTAYO development and commercialization require alignment through joint committees, which can slow Regeneron's ability to respond to market opportunities that Sanofi may not prioritize equally. Leadership's challenge is navigating the governance structure effectively enough to advance Regeneron's priorities while sustaining the partnership relationship that provides the commercial scale on which Regeneron's current commercial success depends.

How does the Regeneron Genetics Center create long-term strategic advantage?
The Regeneron Genetics Center, established in partnership with Geisinger Health System and subsequently expanded with additional partners, has assembled human exome and whole-genome sequencing data linked to detailed medical records for hundreds of thousands of patients. This dataset enables Regeneron scientists to identify rare genetic variants that are associated with disease protection or disease risk in humans – natural experiments that validate drug targets in the species that matters most for pharmaceutical development efficacy. Targets validated by human genetic evidence have higher development success rates than targets identified by other methods, making the Regeneron Genetics Center a competitive advantage in target identification that improves the probability-adjusted returns on Regeneron's R&D pipeline. Leadership investment in the Genetics Center is strategic rather than commercial – the benefits appear years later when drug candidates generated from genetics-validated targets succeed in clinical development at higher rates than the industry baseline.

How should Regeneron respond to the Inflation Reduction Act's drug pricing provisions?
The IRA's Medicare drug price negotiation program represents a structural change in the pharmaceutical pricing environment that Regeneron must address as a strategic matter rather than as a regulatory compliance issue. For EYLEA, Medicare Part B negotiation has already established a negotiated price that reduces net revenue from Medicare beneficiaries specifically – a significant impact given that wet AMD predominantly affects elderly Medicare patients. The potential future application of IRA negotiation to DUPIXENT as it ages into the small molecule exemption-eligible category requires Regeneron to evaluate how the IRA's structure affects the expected value of innovation investment in the indication categories most exposed to Medicare negotiation. Leadership engagement with health policy on IRA implementation – working with industry groups, engaging with policymakers on the innovation impact of specific negotiation parameters, and demonstrating through R&D investment data how pricing pressure affects development decisions – reflects both the company's commercial interests and its genuine stake in policy outcomes that affect the broader pharmaceutical innovation environment.

Also practice

One full session free. No account required. Real, specific feedback.